Aspergillus Drugs Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025

Published Date: 16-Jul-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-4428 Status : Published

Global demand for aspergillus drugs market was valued at approximately USD 3556.41 million in 2018 and is expected to generate revenue of around USD 4893.75 million by end of 2025, growing at a CAGR of around 4.68% between 2019 and 2025.

Description

The report covers forecast and analysis for the aspergillus drugs market on a global and regional level. The study provides historic data from 2015 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the aspergillus drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities and various trends in the aspergillus drugs market on a global level.

As per the report, the global demand for aspergillus drugs market was valued at approximately USD 3556.41 million in 2018 and is expected to generate revenue of around USD 4893.75 million by end of 2025, growing at a CAGR of around 4.68% between 2019 and 2025.

Global Aspergillus Drugs Market

Aspergillus causes the infection Aspergillosis; Aspergillus (a type of fungus) is a common mold present both indoor and outdoor. People everyday breathe Aspergillus spores but do not fall ill. However, individuals with weakened immune systems or lung diseases have an increased risk of developing Aspergillus-related health issues. Aspergillus causes health issues that include allergic reactions, pulmonary infections, and other organs diseases. In addition, a powerful pipeline will result in the growth of therapies with new processes that have better tolerance and efficacy. The existence of numerous promising therapeutic agents in the pipeline increases the demand for therapeutic regimen and expands the therapy choices available. The Aspergillus Website, financed by the Fungal Infection Trust in collaboration with the University of Manchester, was developed to raise awareness of aspergillosis and other illnesses and therapy choices and to prevent delay in diagnosis. Detailed information about the Aspergillus fungus and the diseases it causes is provided on the site.

Based on product type, the market is segmented triazoles and others. Generic drug development is easy and takes less time than innovative drugs and also needs minimal R&D spending. Thus, the introduction of generic drugs at lower price than the innovative drugs hamper the development of the market for aspergillosis drugs.

 In 2017, North America retained its dominant share in the global aspergillosis drugs market. The region's development can be ascribed to increased infectious disease incidence. The rise in incidence has raised clinical urgency to boost the use of these drugs and has encouraged the creation of innovative drugs with the FDA approvals for fast-track use. Moreover, the existence of established pharmaceutical companies continuously striving for comprehensive marketing of their drugs and improving their geographical reach, is expected to be a main factor in the regional market's development. During the forecast period, the Asia Pacific market is estimated to have the highest CAGR. The presence of an enormous target population base, increased disposable income and drug accessibility, and elevated unmet clinical needs contribute to regional market growth. Global players are thus concentrating on heavy investment in the R&D activities as well as marketing branded medicines in the area at a comparatively low cost. In 2017, Japan held a substantial share of the APAC market due to increased medical spending and increased coverage of insurance.

Some of the key players in aspergillosis drugs market t include stellas Pharma, Gilead, Johnson & Johnson Services, Merck Sharp & Dohme, and Pfizer among others.

Global Aspergillus Drugs Market: Product Type Segment Analysis

  • Triazoles
  • Others

Global Aspergillus Drugs Market: Regional Segment Analysis 

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Aspergillus Drugs, 2015–2025 (USD Million)
    • 2.2. Aspergillus Drugs: Snapshot
  • Chapter 3. Aspergillus Drugs – Industry Analysis
    • 3.1. Aspergillus Drugs: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government Funding and Support
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market Attractiveness Analysis by Product
      • 3.6.2. Market Attractiveness Analysis by Region
  • Chapter 4. Aspergillus Drugs– Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Aspergillus Drugs: Company Market Share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launches
      • 4.2.3. Agreements, Partnerships, Cullaborations and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
    • 4.3. Price Trend Analysis
  • Chapter 5. Global Aspergillus Drugs –Product Analysis
    • 5.1. Global Aspergillus Drugs Overview: by Product Type
      • 5.1.1. Global Aspergillus Drugs Share, by Product, 2018 and 2025
    • 5.2. Triazules
      • 5.2.1. Global Aspergillus Drugs by Triazules, 2015–2025 (USD Million)
    • 5.3. Others
      • 5.3.1. Global Aspergillus Drugs by Type 2, 2015–2025 (USD Million)
  • Chapter 6. Global Aspergillus Drugs - Regional Analysis
    • 6.1. Global Aspergillus Drugs Overview: by Region
      • 6.1.1. Global Aspergillus DrugsShare, by Region, 2018 and 2025
    • 6.2. North America
      • 6.2.1. North America Aspergillus Drugs, 2015–2025 (USD Million)
      • 6.2.2. North America Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.2.3. The U.S.
        • 6.2.3.1. The U.S. Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.2.4. Rest Of North America
        • 6.2.4.1. Rest Of North America Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
    • 6.3. Europe
      • 6.3.1. Europe Aspergillus Drugs, 2015–2025 (USD Million)
      • 6.3.2. Europe Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.3.3. UK
        • 6.3.3.1. U.K.Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.3.4. France
        • 6.3.4.1. France Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.3.5. Germany
        • 6.3.5.1. Germany Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.3.6. Rest Of Europe
        • 6.3.6.1. Rest Of Europe Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Aspergillus Drugs, 2015–2025 (USD Million)
      • 6.4.2. Asia Pacific Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.4.3. China
        • 6.4.3.1. China Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.4.4. Japan
        • 6.4.4.1. Japan Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.4.5. India
        • 6.4.5.1. India Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.4.6. Rest Of Asia Pacific
        • 6.4.6.1. Rest Of Asia Pacific Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
    • 6.5. Latin America
      • 6.5.1. Latin America Aspergillus Drugs, 2015–2025 (USD Million)
      • 6.5.2. Latin America Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.5.3. Brazil
        • 6.5.3.1. Brazil Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
      • 6.5.4. Rest of Latin America
        • 6.5.4.1. Rest of Latin America Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
    • 6.6. The Middle East and Africa
      • 6.6.1. The Middle East and Africa Aspergillus Drugs, 2015–2025 (USD Million)
      • 6.6.2. The Middle East and Africa Aspergillus Drugs Revenue, by Product, 2015–2025 (USD Million)
  • Chapter 7. Company Profiles
    • 7.1. Stellas Pharma
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Gilead
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Johnson & Johnson Services
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Merck Sharp & Dohme
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Pfizer
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
      • 7.5.6. Business Strategy
      • 7.5.7. Recent Development

Methodology

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social